ATE551056T1 - Mittel zur hemmung der körpergewichtszunahme - Google Patents

Mittel zur hemmung der körpergewichtszunahme

Info

Publication number: ATE551056T1
Authority: AT; Austria
Prior art keywords: body weight; weight gain; agent; inhibiting body; provides
Prior art date: 2002-12-27

Application number

AT03768195T

Other languages

English (en)

Inventor

Zen-Ichi Terashita

Keiji Kusumoto

Fuminari Yamaguchi

Yoshimi Imura

Original Assignee

Takeda Pharmaceutical

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-27

Filing date

2003-12-25

Publication date

2012-04-15

2003-12-25 Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical

2012-04-15 Application granted granted Critical

2012-04-15 Publication of ATE551056T1 publication Critical patent/ATE551056T1/de

Links

230000037396 body weight Effects 0.000 title abstract 3
235000019786 weight gain Nutrition 0.000 title abstract 2
230000002401 inhibitory effect Effects 0.000 title 1
239000008177 pharmaceutical agent Substances 0.000 abstract 2
102000005862 Angiotensin II Human genes 0.000 abstract 1
101800000733 Angiotensin-2 Proteins 0.000 abstract 1
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 abstract 1
102000000536 PPAR gamma Human genes 0.000 abstract 1
108010016731 PPAR gamma Proteins 0.000 abstract 1
230000001270 agonistic effect Effects 0.000 abstract 1
229950006323 angiotensin ii Drugs 0.000 abstract 1
230000003042 antagnostic effect Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
229940002612 prodrug Drugs 0.000 abstract 1
239000000651 prodrug Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1
230000001629 suppression Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Child & Adolescent Psychology (AREA)
Hematology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Anti-Oxidant Or Stabilizer Compositions (AREA)
Lubricants (AREA)
Registering, Tensioning, Guiding Webs, And Rollers Therefor (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT03768195T 2002-12-27 2003-12-25 Mittel zur hemmung der körpergewichtszunahme ATE551056T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2002380386		2002-12-27
PCT/JP2003/016656 WO2004060399A1 (ja)	2002-12-27	2003-12-25	体重増加抑制剤

Publications (1)

Publication Number	Publication Date
ATE551056T1 true ATE551056T1 (de)	2012-04-15

Family

ID=32708435

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03768195T ATE551056T1 (de)	2002-12-27	2003-12-25	Mittel zur hemmung der körpergewichtszunahme

Country Status (8)

Country	Link
US (1)	US7582662B2 (de)
EP (1)	EP1579872B8 (de)
KR (1)	KR101092279B1 (de)
CN (1)	CN100438911C (de)
AT (1)	ATE551056T1 (de)
AU (1)	AU2003292775A1 (de)
CA (1)	CA2511737A1 (de)
WO (1)	WO2004060399A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE0300988D0 (sv) *	2003-04-03	2003-04-03	Astrazeneca Ab	New use
UY29155A1 (es) *	2004-10-07	2006-02-24	Takeda Pharmaceutical	Un agente para la profilaxis o tratamietno del sindrome metabolico
US20060084637A1 (en) *	2004-10-18	2006-04-20	Maria Alemany	Methods of using fatty-acid esters of estrogens and thermogenic compounds for reducing the body weight of a mammal and compositions containing the same
AR065850A1 (es) *	2007-03-28	2009-07-08	Takeda Pharmaceutical	Composicion farmaceutica solida que comprende un derivado de benzimidazol-7-carboxilato y un agente de control de ph

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6107323A (en) *	1996-04-05	2000-08-22	Takeda Chemical Industries, Ltd.	Pharmaceutical composition
JP3003030B2 (ja)	1997-05-26	2000-01-24	武田薬品工業株式会社	アミノベンゼン化合物の製造法
US6177587B1 (en) *	1997-05-26	2001-01-23	Takeda Chemical Industries, Ltd.	Production method of aminobenzene compound
ES2214013T3 (es) *	1998-03-04	2004-09-01	Takeda Chemical Industries Ltd	Preparacion de liberacion sostenida para un antagonista de aii, su produccion y su uso.
MY123337A (en) *	1998-05-11	2006-05-31	Takeda Chemical Industries Ltd	Oxyiminoalkanoic acid derivatives.
EP1197226B1 (de)	1999-07-21	2007-11-21	Takeda Pharmaceutical Company Limited	Mittel zur verbesserung der erkrankungen nach zerebralen durchblutungsstörungen sowie zur verhinderung deren fortschrittens
EP1304121A4 (de)	1999-11-10	2004-06-23	Takeda Chemical Industries Ltd	Inhibitoren der koerpergewichtszunahme
PL356422A1 (en)	2000-02-18	2004-06-28	Takeda Chemical Industries, Ltd.	Tnf-alpha inhibitors
US20030068374A1 (en) *	2000-02-21	2003-04-10	Shigeru Kamei	Sustained release preparations of physiologically active compound hardly soluble in water and production process and use of the same
KR20020089437A (ko)	2000-04-12	2002-11-29	노파르티스 아게	유기 화합물의 배합
US20030083342A1 (en) *	2002-08-27	2003-05-01	Steele Ronald Edward	Combination of organic compounds
CA2405793A1 (en) *	2000-04-12	2001-10-18	Novartis Ag	Combination of organic compounds
PE20020617A1 (es)	2000-08-22	2002-08-05	Novartis Ag	Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina
CA2420055C (en)	2000-08-25	2010-06-01	Takeda Chemical Industries, Ltd.	Fibrinogen-lowering agent
WO2002074340A1 (fr) *	2001-03-16	2002-09-26	Takeda Chemical Industries, Ltd.	Procede de fabrication d'une preparation a liberation continue
US20040219208A1 (en)	2001-08-03	2004-11-04	Ryu Kawamura	Sustained-release medicines
AU2002349673A1 (en) *	2001-12-03	2003-06-17	Takeda Chemical Industries, Ltd.	Insulin resistance improving agents

2003
- 2003-12-25 AT AT03768195T patent/ATE551056T1/de active
- 2003-12-25 WO PCT/JP2003/016656 patent/WO2004060399A1/ja not_active Ceased
- 2003-12-25 CA CA002511737A patent/CA2511737A1/en not_active Abandoned
- 2003-12-25 CN CNB2003801100435A patent/CN100438911C/zh not_active Expired - Fee Related
- 2003-12-25 EP EP03768195A patent/EP1579872B8/de not_active Expired - Lifetime
- 2003-12-25 KR KR1020057012069A patent/KR101092279B1/ko not_active Expired - Fee Related
- 2003-12-25 AU AU2003292775A patent/AU2003292775A1/en not_active Abandoned
- 2003-12-25 US US10/540,369 patent/US7582662B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP1579872B8 (de)	2012-11-07
WO2004060399A1 (ja)	2004-07-22
US20060069133A1 (en)	2006-03-30
EP1579872A4 (de)	2006-03-22
CN1756567A (zh)	2006-04-05
US7582662B2 (en)	2009-09-01
EP1579872A1 (de)	2005-09-28
HK1083587A1 (en)	2006-07-07
CA2511737A1 (en)	2004-07-22
KR20050085905A (ko)	2005-08-29
CN100438911C (zh)	2008-12-03
AU2003292775A1 (en)	2004-07-29
EP1579872B1 (de)	2012-03-28
KR101092279B1 (ko)	2011-12-13

Publication	Publication Date	Title
WO2003096990A3 (en)	2004-02-26	Protein cages for the delivery of medical imaging and therapy
DE60231407D1 (de)	2009-04-16	Hemmende antikörper der her3-aktivität
TNSN07208A1 (en)	2008-11-21	3,5-DISUBTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO [4,5-d] PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF
WO2006059234A3 (en)	2006-07-20	Bicyclic amides as kinase inhibitors
ATE442142T1 (de)	2009-09-15	Fredericamycin-derivate als arzneimittel zur tumorbehandlung
BR0212078A (pt)	2004-09-28	Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto
AP2004003069A0 (en)	2004-06-30	3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof.
WO2004009558A3 (en)	2004-04-15	Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
WO2002100390A3 (en)	2004-04-22	Improved method of treating the syndrome of coronary heart disease risk factors in humans
WO2005056524A3 (en)	2005-09-22	Therapeutic agents useful for treating pain
TNSN04203A1 (en)	2007-03-12	Benzoxazinone-derived compounds, their preparation and use as medicaments
WO2003084611A8 (en)	2004-04-08	Depsipeptide for therapy of kidney cancer
EA200600971A1 (ru)	2006-12-29	Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
ATE487720T1 (de)	2010-11-15	5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer
TR200002969T2 (tr)	2001-01-22	Farmasötik bileşim.
IN2005KO00312A (de)	2015-08-14
MXPA06014182A (es)	2007-06-25	Nucleosidos de 3-??-d-ribofuranosiltiazolo[4,5-d]piridimina y usos de los mismos.
TW200420554A (en)	2004-10-16	A intra-airway administrating preparation
ATE326451T1 (de)	2006-06-15	Chinazolin derivate und therapeutische verwendungen davon
EP1579872A4 (de)	2006-03-22	Mittel zur hemmung der körpergewichtszunahme
EA200601592A1 (ru)	2006-12-29	Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора
WO2008060535A3 (en)	2009-04-09	Use of reversine and analogs for treatment of cancer
EP1695969A4 (de)	2008-11-26	Alpha-aminosäurederivate und deren verwendung als medizin
BRPI0410576A (pt)	2006-06-20	composto quìmico, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método para o tratamento, prevenção ou alìvio de uma doença ou um distúrbio ou condição de um corpo de animal vivo
WO2005000406A3 (en)	2005-06-23	Treatment of amyloid- and epileptogenesis-associated diseases